

Special Issue

Population Immunity and Persistence to SARS-CoV-2 Induced by Infection and Vaccination, Protection against New Infections and Implication for Further Vaccination

Message from the Guest Editor

Although the World Health Organization declared the end to COVID-19's emergency phase, SARS-CoV-2 will be around for a long time and the risk of new variants remains. Having a good knowledge of the population immunity landscape and dynamics and understanding its protection against infections of variants and the severity after infections are critical for policymaking on actions that countries should take in the new phase of the COVID-19 pandemic. The Special Issue aims to collect the latest research results on the sero-epidemiological characteristics of SARS-CoV-2 infections and vaccination. With this in mind, we are pleased to invite the submission of original research articles and reviews investigating the infection incidence and its severity, population immunity landscape, the kinetics of antibodies following prior infections (with any variant), vaccination (particularly post-licensure), or both (hybrid immunity), protection (and cross-protection) against new variants infections, and providing new ideas for the COVID-19 vaccination strategy in the future.

Guest Editor

Dr. Juan Yang

School of Public Health, Fudan University, Shanghai, China

Deadline for manuscript submissions

closed (31 October 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/174292

Vaccines

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).